New drug with chemotherapy for recurrent brain tumors
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug (L19TNF) combined with standard chemotherapy for people whose brain tumor (IDH-mutant glioma) has returned after earlier treatment. It aims to see if this combination is safe and helps control the tumor better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- Your brain tumor must have come back after previous chemotherapy, and it must have a specific gene change called IDH-mutant.
- One of these tumor types: oligodendroglioma or astrocytoma (a doctor can confirm).
- You need to be in generally good health (able to care for yourself and do daily activities).
- You must be willing to practice effective birth control during and for 6 months after treatment (if applicable).
- No other cancer treatments (except surgery) within the last 4 weeks, and no live vaccines within 4 weeks before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.
This Phase 1/2 study tests whether adding a drug called L19TNF to standard chemoradiotherapy is safe and may work better than standard treatment alone for newly diagnosed glioblastoma. If you qualify, you would be closely monitored for side effects and treatment response.
This trial tests a new drug called CT-179 for people with glioblastoma, an aggressive type of brain cancer. The drug targets a protein that helps cancer cells grow, and the goal is to see if it is safe and whether it can slow the tumor down.
This study tests FT536, a new cell-based treatment, for people with a specific type of brain cancer (WHO Grade 4 astrocytoma) that has come back after standard treatment. The trial combines the new therapy with surgery to see if it can help stop the cancer from growing further.
This trial tests a new treatment that combines a specially designed virus to attack tumor cells with an immunotherapy drug to help the immune system fight the cancer. It is for people whose high-grade glioma (a type of brain tumor) has come back after standard treatment.
This trial tests a new drug (KH617) for people whose glioblastoma has returned after the first round of standard treatment. The drug is hoped to slow or stop the tumor's growth. You must have a specific genetic marker (MGMT unmethylated) and be in fairly good health to join.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.